THE Therapeutic Goods Administration has added riluzole (Teglutik) from Seqirus to its list of designated orphan drugs.
Teglutik is a liquid oral suspension used for the treatment of patients with amyotrophic lateral sclerosis, also known as ALS.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Feb 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Feb 17